指南与共识产科母胎医学

母胎医学会咨询系列第52号:胎儿生长受限的诊断与管理

Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction: (Replaces Clinical Guideline Number 3, April 2012).
指南 / 共识 · Am J Obstet Gynecol · 2020-05-12

该咨询由母胎医学会制定,提出胎儿生长受限的循证标准化产前诊断与管理路径。胎儿生长受限发生率最高达10%,是婴儿发病和死亡的主要原因。文件给出21条推荐,涵盖定义、筛查、多普勒监测、分娩时机与产前激素使用等。

要点

  • 胎儿生长受限定义为超声估计胎儿体重或腹围低于同孕龄第10百分位。
  • 脐动脉舒张末期血流缺失者建议33-34周分娩,反向者建议30-32周分娩。
  • 不推荐低分子肝素用于预防复发性胎儿生长受限,也不推荐西地那非或限制活动治疗。

核心结论

  • 胎儿生长受限应基于超声估计胎儿体重或腹围低于同孕龄第10百分位定义,并采用人群胎儿生长参考。
  • 根据脐动脉多普勒血流情况分层管理并确定分娩时机,是改善围产结局的关键。

研究设计与样本

  • 母胎医学会咨询系列,替代2012年4月第3号临床指南,采用GRADE分级给出推荐。

主要发现

  • 胎儿生长受限可源于母体、胎儿和胎盘多种情况,发生率最高达10%。
  • 该问题诊断标准不一、检出率较低,且预防和治疗选择有限。
  • 文件提出21条推荐,覆盖定义、诊断检测、多普勒监测、分娩时机和产前用药。

关键数值与推荐

  • 推荐胎儿生长受限定义为超声估计胎儿体重或腹围低于同孕龄第10百分位(GRADE 1B)。
  • 推荐使用人群胎儿生长参考如Hadlock确定胎儿体重百分位(GRADE 1B)。
  • 不推荐低分子肝素仅用于预防复发性胎儿生长受限(GRADE 1B)。
  • 不推荐西地那非或限制活动用于胎儿生长受限的宫内治疗(GRADE 1B)。
  • 早发型胎儿生长受限(<32周)推荐行详细产科超声检查(CPT 76811)(GRADE 1B)。

临床怎么用

  • 以超声估计胎儿体重或腹围低于第10百分位统一诊断胎儿生长受限。
  • 确诊后行连续脐动脉多普勒,按血流分级决定监测频率与分娩时机。
  • 早发型或伴畸形/羊水过多者提供染色体微阵列分析等诊断检测。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fetal growth restriction can result from a variety of maternal, fetal, and placental conditions. It occurs in up to 10% of pregnancies and is a leading cause of infant morbidity and mortality. This complex obstetrical problem has disparate published diagnostic criteria, relatively low detection rates, and limited preventative and treatment options. The purpose of this Consult is to outline an evidence-based, standardized approach for the prenatal diagnosis and management of fetal growth restriction. The recommendations of the Society for Maternal-Fetal Medicine are as follows: (1) we recommend that fetal growth restriction be defined as an ultrasonographic estimated fetal weight or abdominal circumference below the 10th percentile for gestational age (GRADE 1B); (2) we recommend the use of population-based fetal growth references (such as Hadlock) in determining fetal weight percentiles (GRADE 1B); (3) we recommend against the use of low-molecular-weight heparin for the sole indication of prevention of recurrent fetal growth restriction (GRADE 1B); (4) we recommend against the use of sildenafil or activity restriction for in utero treatment of fetal growth restriction (GRADE 1B); (5) we recommend that a detailed obstetrical ultrasound examination (current procedural terminology code 76811) be performed with early-onset fetal growth restriction (<32 weeks of gestation) (GRADE 1B); (6) we recommend that women be offered fetal diagnostic testing, including chromosomal microarray analysis, when fetal growth restriction is detected and a fetal malformation, polyhydramnios, or both are also present regardless of gestational age (GRADE 1B); (7) we recommend that pregnant women be offered prenatal diagnostic testing with chromosomal microarray analysis when unexplained isolated fetal growth restriction is diagnosed at <32 weeks of gestation (GRADE 1C); (8) we recommend against screening for toxoplasmosis, rubella, or herpes in pregnancies with fetal growth restriction in the absence of other risk factors and recommend polymerase chain reaction for cytomegalovirus in women with unexplained fetal growth restriction who elect diagnostic testing with amniocentesis (GRADE 1C); (9) we recommend that once fetal growth restriction is diagnosed, serial umbilical artery Doppler assessment should be performed to assess for deterioration (GRADE 1C); (10) with decreased end-diastolic velocity (ie, flow ratios greater than the 95th percentile) or in pregnancies with severe fetal growth restriction (estimated fetal weight less than the third percentile), we suggest weekly umbilical artery Doppler evaluation (GRADE 2C); (11) we recommend Doppler assessment up to 2-3 times per week when umbilical artery absent end-diastolic velocity is detected (GRADE 1C); (12) in the setting of reversed end-diastolic velocity, we suggest hospitalization, administration of antenatal corticosteroids, heightened surveillance with cardiotocography at least 1-2 times per day, and consideration of delivery depending on the entire clinical picture and results of additional evaluation of fetal well-being (GRADE 2C); (13) we suggest that Doppler assessment of the ductus venosus, middle cerebral artery, or uterine artery not be used for routine clinical management of early- or late-onset fetal growth restriction (GRADE 2B); (14) we suggest weekly cardiotocography testing after viability for fetal growth restriction without absent/reversed end-diastolic velocity and that the frequency be increased when fetal growth restriction is complicated by absent/reversed end-diastolic velocity or other comorbidities or risk factors (GRADE 2C); (15) we recommend delivery at 37 weeks of gestation in pregnancies with fetal growth restriction and an umbilical artery Doppler waveform with decreased diastolic flow but without absent/reversed end-diastolic velocity or with severe fetal growth restriction with estimated fetal weight less than the third percentile (GRADE 1B); (16) we recommend delivery at 33-34 weeks of gestation for pregnancies with fetal growth restriction and absent end-diastolic velocity (GRADE 1B); (17) we recommend delivery at 30-32 weeks of gestation for pregnancies with fetal growth restriction and reversed end-diastolic velocity (GRADE 1B); (18) we suggest delivery at 38-39 weeks of gestation with fetal growth restriction when the estimated fetal weight is between the 3rd and 10th percentile and the umbilical artery Doppler is normal (GRADE 2C); (19) we suggest that for pregnancies with fetal growth restriction complicated by absent/reversed end-diastolic velocity, cesarean delivery should be considered based on the entire clinical scenario (GRADE 2C); (20) we recommend the use of antenatal corticosteroids if delivery is anticipated before 33 6/7 weeks of gestation or for pregnancies between 34 0/7 and 36 6/7 weeks of gestation in women without contraindications who are at risk of preterm delivery within 7 days and who have not received a prior course of antenatal corticosteroids (GRADE 1A); and (21) we recommend intrapartum magnesium sulfate for fetal and neonatal neuroprotection for women with pregnancies that are <32 weeks of gestation (GRADE 1A).

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Martins JG, Biggio JR, Abuhamad A, et al. Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction: (Replaces Clinical Guideline Number 3, April 2012). Am J Obstet Gynecol. 2020. PMID: 32407785. doi:10.1016/j.ajog.2020.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。